Q3 Earnings Forecast for CG Oncology Issued By HC Wainwright

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of CG Oncology in a report issued on Thursday, August 6th. HC Wainwright analyst A. Maldonado now expects that the company will earn ($0.96) per share for the quarter, down from their prior estimate of ($0.78). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for CG Oncology’s Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($3.60) EPS, FY2027 earnings at ($2.83) EPS and FY2028 earnings at ($0.65) EPS.

CGON has been the subject of several other research reports. Wedbush boosted their price objective on shares of CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of CG Oncology from a “sell” rating to a “strong sell” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a report on Friday, July 17th. Truist Financial raised their price target on shares of CG Oncology from $82.00 to $85.00 and gave the company a “buy” rating in a report on Friday, August 7th. Finally, JPMorgan Chase & Co. boosted their price target on shares of CG Oncology from $91.00 to $96.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, CG Oncology currently has a consensus rating of “Moderate Buy” and an average target price of $83.18.

CG Oncology Trading Up 0.6%

Shares of CG Oncology stock opened at $77.03 on Monday. CG Oncology has a 12-month low of $24.10 and a 12-month high of $77.49. The company has a market cap of $6.83 billion, a price-to-earnings ratio of -28.64 and a beta of 0.23. The company’s 50-day moving average price is $67.90 and its 200-day moving average price is $64.31.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.24). CG Oncology had a negative return on equity of 26.58% and a negative net margin of 3,602.68%.The company had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.36 million.

Hedge Funds Weigh In On CG Oncology

A number of institutional investors have recently made changes to their positions in CGON. AQR Capital Management LLC bought a new stake in shares of CG Oncology during the 1st quarter worth $475,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in CG Oncology by 18.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,522 shares of the company’s stock valued at $876,000 after purchasing an additional 5,442 shares in the last quarter. Millennium Management LLC raised its position in CG Oncology by 139.4% during the first quarter. Millennium Management LLC now owns 596,056 shares of the company’s stock valued at $14,597,000 after purchasing an additional 347,055 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in CG Oncology by 42.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 179,363 shares of the company’s stock valued at $4,393,000 after purchasing an additional 53,461 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in CG Oncology by 12.3% during the second quarter. Legal & General Group Plc now owns 44,354 shares of the company’s stock worth $1,153,000 after purchasing an additional 4,847 shares during the last quarter. Institutional investors own 26.56% of the company’s stock.

Insider Activity

In related news, Director Leonard E. Post sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $70.00, for a total value of $350,000.00. Following the sale, the director directly owned 5,000 shares of the company’s stock, valued at $350,000. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brian Guan-Chyun Liu bought 371,085 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were bought at an average price of $66.87 per share, with a total value of $24,814,453.95. Following the completion of the transaction, the director owned 1,886,236 shares of the company’s stock, valued at $126,132,601.32. The trade was a 24.49% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders sold 37,129 shares of company stock worth $2,663,817. 4.80% of the stock is currently owned by insiders.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.